Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phio Pharmaceuticals Corp. (NASDAQ: PHIO) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phio is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology in immuno-oncology, with a lead program, PH-762, targeting the PD-1 gene in skin cancers.
Through this page, you can review current and historical Forms 8-K in which Phio reports material events. Recent 8-K filings describe clinical milestones for the Phase 1b trial of PH-762 (NCT 06014086), such as completion of enrollment, interim pathology results, and Safety Monitoring Committee findings that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed at reported dose levels. Other 8-Ks detail warrant inducement agreements, gross proceeds from warrant exercises, and the terms of new warrants and placement agent warrants.
Phio’s proxy materials, including its Definitive Proxy Statement on Schedule DEF 14A, outline governance and compensation matters. These filings cover the election of directors, ratification of the independent registered public accounting firm, amendments to the 2020 Long Term Incentive Plan to increase share availability, and advisory votes on executive compensation and the frequency of such votes. They also describe the conduct of the annual meeting and voting results on each proposal.
As Phio advances its INTASYL platform and PH-762 program, investors can use this filings page to monitor financial reporting, capital structure changes, and corporate actions. Stock Titan enhances these documents with AI-powered summaries that highlight key points in complex filings, helping readers quickly identify items such as clinical development updates, financing terms, and board decisions without manually parsing every section.
In addition, the filings page links to disclosures about nonclinical protocol acceptance by the FDA, agreements for cGMP manufacturing of PH-762, and other events that influence the company’s development and financing strategy. For those analyzing PHIO, this centralized view of 8-Ks, proxy statements, and related filings offers a concise way to follow the regulatory record that underpins Phio’s public communications.
Phio Pharmaceuticals Corp. director Patricia A. Bradford reported a change in beneficial ownership related to restricted stock units. The filing shows an acquisition of 18,800 shares of common stock issued to satisfy restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction, Ms. Bradford beneficially owns 27,151 shares, a total that the filing indicates includes shares underlying unvested restricted stock units. The reported share counts have been adjusted to reflect prior reverse stock splits. The transaction was reported as an acquisition at $0 per share, consistent with issuance upon vesting of RSUs.
Robert J. Bitterman, Chairman, President and CEO of Phio Pharmaceuticals Corp. (PHIO), reported equity transactions on a Form 4 filed for activity dated 09/11/2025. The filing shows 4,111 shares were withheld by the issuer to satisfy tax withholding related to vested restricted stock units; no shares were sold.
The reporting person was also granted 250,000 restricted stock units on that date that vest on the first annual anniversary of the grant. After these transactions the filing reports 271,421 shares of common stock beneficially owned by Mr. Bitterman. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Phio Pharmaceuticals Corp. filed a Form S-8 to register 1,005,555 additional shares of its common stock, par value $0.0001, for issuance under the Phio Pharmaceuticals Corp. amended and restated 2020 Long Term Incentive Plan. This filing expands the pool of shares available for equity-based awards such as stock options or restricted stock units to employees, directors, and other eligible participants under the 2020 Plan.
The company uses General Instruction E to Form S-8, incorporating by reference its prior S-8 registrations for the same plan and its ongoing Exchange Act reports, so new disclosures here are limited mainly to the additional registered shares and updated exhibits.
Phio Pharmaceuticals Corp. reported that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, which is scheduled for September 8-10, 2025. The company also noted that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer, indicating continued progression of this early-stage study.
Phio Pharmaceuticals Corp. (PHIO) reported interim financials showing continued operating losses and active financing and warrant activity. The company recorded an operating loss of $2,309 and a net loss of $2,166 for the most recent quarter presented, compared with operating loss of $1,914 and net loss of $1,846 in the prior period. Cash flows show a net increase in cash of $5,393 for the period and modest investing outflows.
The filing discloses multiple financings and warrant issuances: net proceeds of approximately $2.646 million from a July 2024 financing, and subsequent registered direct and private placements in January 2025 generating approximately $2.9M, $2.2M, $1.6M and other raises. The company completed a 1-for-9 reverse stock split and recorded significant non-cash equity issuance costs (about $2.4M for warrant fair value and ~$0.2M placement agent warrants). Clinical and collaboration expenses include $4,000,000 incurred for a Phase 1 trial of PH-762. The report lists customary risk factors, reliance on third parties, and material uncertainty around future capital needs.
Phio Pharmaceuticals Corp. (PHIO) filed a Form D announcing a Rule 506(b) private placement that opened 28-Jul-2025.
- Target size: up to $5.08 million in warrants and the underlying common shares.
- Raised to date: $232,149 (≈4.6% of target) from two accredited investors; minimum investment $0.
- Remaining to sell: $4.85 million.
- Broker compensation: $261,753 cash (≈5.2% of capital raised) plus 69,645 warrants (7,500 exercisable at $2.8125; 62,145 at $3.4188).
- Securities offered: options/warrants and the shares issuable upon exercise; no debt or pooled-fund interests.
- Offering duration: expected to close within one year; not linked to a business combination.
- Issuer profile: Delaware-incorporated biotechnology company headquartered in King of Prussia, PA; revenue size undisclosed.
No proceeds are slated for payments to directors, officers or promoters. Reliance on Reg D limits the sale to accredited investors and keeps detailed financials private. Execution risk remains until the full amount is subscribed.